David Landman, MD, FACP, FIDSA

Education and Training

Fellowship:

• Infectious Diseases
  SUNY Downstate Medical Center
  1987-1989

Residency:

• Internal Medicine
  Brookdale Hospital Medical Center
  1084-1987

Medical School:

• SUNY Downstate Medical Center
  1980-1984

Career / Research Interests

Antimicrobial resistance, including molecular and clinical epidemiology, mechanisms of resistance, activity of investigational agents, and antimicrobial combinations.

• Landman D, Butnariu M, Bratu S, Quale J. Genetic relatedness of multidrug-resistant Acinetobacter baumannii endemic to New York City. Epidemiol Infect. 2009; 137:174-80.
• Kochar S, Sheard T, Sharma R, Hui A, Tolentino E, Allen G, Landman D, Bratu S, Augenbraun M, Quale J. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2009 May;30(5):447-52.
• Bratu S, Landman D, George A, Salvani J, and Quale J. Correlation of the Expression of acrB and the Regulatory Genes marA, soxS, and ramA with Antimicrobial Resistance in Clinical Isolates of Klebsiella pneumoniae Endemic to New York City. J Antimicrob Chemother 2009; 64:278-83.
• Landman D, Bratu S, and Quale J. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J Med Microbiol 2009; 58:1303-8.
• Landman D, Babu E, Shah N, Kelly P, Backer M, Bratu S, Quale J. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J Antimicrob Chemother 2010; 65: 2123-7.
• Landman D, Urban C, Backer M, Kelly P, Shah N, Babu E, Bratu S, Quale J. Susceptibility profiles, molecular epidemiology, and detection of KPC-producing Escherichia coli isolates from the New York City vicinity. J Clin Microbiol 2010; 48: 4604-7.
• Landman D, Kelly P, Backer M, Babu E, Shah N, Bratu S, Quale J. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother 2011;66:332-4.
• Landman D, Salamera J, Singh M, Quale J. Accuracy of carbapenem non-susceptibility for identification of KPC-possessing Enterobacteriaceae by use of the revised CLSI breakpoints. J Clin Microbiol 2011; 49:3931-3
• Quale J, Shah N, Kelly P, Babu E, Backer M, Rosas-Garcia G, Salamera J, George A, Bratu S, Landman D. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City. Microb Drug Resist 2012; 18:132-6.
• Landman D, Babu E, Shah N, Kelly P, Olawole O, Backer M, Bratu S, Quale J. Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration. J Antimicrob Chemother 2012; 67:1427-31.
• Landman D, Salamera J, Quale J. Irreproducible and uninterpretable polymyxin b MICs for Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol 2013; 51:4106-11.
• Rose M, Landman D, Quale J. Are community environmental surfaces near hospitals reservoirs for Gram-negative nosocomial pathogens? Am J Infect Control 2014; 42: 346-8.
• Landman D, Singh M, El-Imad B, Milller E, Win T, Quale J. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates. Int J Antimicrob Agents 2014; 43: 527-32.
• Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 2015; 59: 1802-5.
• Abdallah M, Olafisoye O, Cortes C, Urban C, Charles C, Landman D, Quale J. Reduction in the prevalence of carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in New York City. Am J Infect Control 2015; 43: 650-2.
• Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. Activity of imipenem with relebactam against Gram-negative pathogens from New York City. Antimicrob Agents Chemother 2015; 59: 5029-31.
• Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J, Landman D. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 2015; 59: 4856-60.